Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Mar 16, 2011


Agendia has made three appointments to its executive team. David Macdonald has been named chief operating officer, Mark Willig is executive vice president of North American sales, and Doug Bradley has been appointed vice president of global marketing.

Macdonald has been involved in commercializing clinical diagnostics and lab services tools at Nanogen, AltheaDx, Behring Diagnostics, and the Nichols Institute. Willig was general manager and chief commercial officer at Exiqon, vice president of global sales for Thermo Fisher's pathology business, and worked at Myriad Genetics and Abbott Diagnostics. Bradley has worked at Coherent Medical, Allergan, SenoRx, and at Vertos Medical.

John Krayacich has joined Exact Sciences as senior vice president of sales and marketing.

Krayacich was most recently president and chief executive officer of two startup biotechnology companies: Ambrose Pharmaceuticals and Marinus Pharmaceuticals. Prior to that, Krayacich held executive positions at Novartis, Pfizer Neurosciences, and Parke-Davis.

Jay Moyes has been appointed to the board of directors at Integrated Diagnostics. Moyes was previously chief financial officer of Myriad Genetics and chief financial officer of XDx. He is currently director and chair of the audit committees of both Osiris Therapeutics and BioCardia.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.